---
canonical_name: Losartan
alternate_names: Losartan Potassium, Cozaar, DuP 753, MK-954
canonical_topic: Losartan for Health & Longevity
short_topic_lc: losartan
creation_date: 2026-1016-0803
creator_ai_fullname: Opus 5.5
ep_keywords: ARBs, Angiotensin II Receptor Blockers, Sartans, Antihypertensives
---

# Losartan for Health & Longevity
<section id="top" markdown="1"></section>  
Evidence Review created on 10/16/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5.5  

**Also known as:** Losartan Potassium, Cozaar, DuP 753, MK-954

  
## Motivation

<!-- This Motivation section was written only after all other sections of the document had been completed, so that it reflects the full scope of the topic. -->

Losartan is a prescription blood pressure medication, taken as an oral tablet, that blocks the action of a hormone that narrows blood vessels, makes the body hold on to salt, and promotes scarring in the heart, kidneys, and arteries. Because high blood pressure is one of the largest modifiable drivers of heart and kidney disease, losartan acts directly on pathways that shape how long and how well people live.

Introduced in the mid-1990s as the first drug of its kind, losartan has been studied in large trials in people with high blood pressure and related heart and kidney conditions. It is now an inexpensive generic. Interest from the longevity field grew from laboratory studies linking this same hormone system to lifespan, which raised the question of whether a familiar blood pressure drug might also act on aging itself.

This review examines what is known about losartan's benefits and risks for health-focused adults, how its effects compare with related drugs, which dosing approaches have been studied, and what monitoring the evidence supports, including for people whose blood pressure is already normal.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**

  
## Recommended Reading

Expert commentary and primary research offering a high-level view of losartan and the angiotensin II receptor pathway it blocks.

<!-- Search statement: Real-time searches were run on 2026-10-16 for losartan (and for its receptor pathway) via web search for each priority expert ("Peter Attia losartan", "Rhonda Patrick losartan", "Huberman Lab losartan", "Chris Kresser losartan", "Life Extension losartan", "lifespan.io losartan") and via each platform's own site search (peterattiamd.com, foundmyfitness.com, hubermanlab.com, chriskresser.com, lifeextension.com, lifespan.io). Among the site searches, only peterattiamd.com returned content that names losartan in a health context (episode #75 on drug recalls; episode #401 mentions losartan only in passing within the history of drug discovery). FoundMyFitness, Chris Kresser and Lifespan.io site searches returned no results for losartan; Lifespan.io returned no article dedicated to losartan or angiotensin receptor blockers; the Huberman Lab and Life Extension site searches did not render results, and web searches surfaced no losartan content from Huberman Lab. A web search restricted to lifeextension.com surfaced the 2015 Life Extension Magazine article "Best Drug To Treat Hypertension", which discusses losartan and the angiotensin receptor blocker class in depth; it was retrieved via d-fetch (d-browser returned "Access Denied"). PubMed was searched for primary research and narrative reviews discussing losartan or angiotensin II type 1 receptor blockade in relation to aging, lifespan, and muscle. -->

* [Best Drug To Treat Hypertension](https://www.lifeextension.com/magazine/2015/3/best-drug-to-treat-hypertension) - William Faloon

  Essay on angiotensin receptor blockers (drugs blocking angiotensin II's main receptor), the class losartan founded: notes losartan may need twice-daily dosing for 24-hour control and argues the class, especially telmisartan, offers metabolic and longevity benefits.

* [Disruption of the Ang II type 1 receptor promotes longevity in mice](https://pubmed.ncbi.nlm.nih.gov/19197138/) - Benigni et al., 2009

  Mice lacking the angiotensin II type 1 (AT1) receptor, the receptor losartan blocks, lived markedly longer with less oxidative damage and more mitochondria (cellular power plants), anchoring the longevity rationale.

* [Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states](https://pubmed.ncbi.nlm.nih.gov/17237794/) - Cohn et al., 2007

  In two mouse models of inherited muscle disease, losartan damped TGF-β (transforming growth factor beta, a scarring signal) and restored muscle repair, the basis for testing it against muscle decline.

* [Renin-angiotensin system inhibitors positively impact on multiple aging regulatory pathways: Could they be used to protect against human aging?](https://pubmed.ncbi.nlm.nih.gov/38924381/) - de Cavanagh et al., 2024

  Narrative review arguing that blocking the renin-angiotensin system (the hormone cascade controlling blood pressure and salt balance), the system losartan targets, engages aging pathways, and proposing human longevity trials.

* [Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol](https://pubmed.ncbi.nlm.nih.gov/11937178/) - Dahlöf et al., 2002

  Landmark Merck-funded trial: in 9,193 adults with hypertension and left ventricular hypertrophy (thickened heart muscle), losartan prevented more strokes than atenolol, a beta-blocker (heart-rate-slowing drug).

No losartan-specific content was found from Rhonda Patrick, Andrew Huberman, Chris Kresser, or Lifespan.io; Peter Attia's site mentions losartan only in passing within a drug-recall episode, which does not discuss it in depth and is therefore not listed.

  
## Grokipedia

<!-- Search statement: grokipedia.com was searched directly on 2026-10-16. Tier 1, d-browser, loaded grokipedia.com/search?q=losartan, which listed 154 results headed by a dedicated "Losartan" article (/page/Losartan). Tier 2, d-fetch, then retrieved the article page itself and confirmed its content. Further tiers were not needed. -->

* [Losartan](https://grokipedia.com/page/Losartan)

  AI-written overview of losartan's pharmacology, approved uses, dosing, kidney-protection trials, and pregnancy warning; useful as quick orientation, though claims need checking against primary sources.

  
## Examine

<!-- Search statement: examine.com was searched directly on 2026-10-16. Tier 1, d-browser, returned a "Vercel Security Checkpoint" bot wall. Tier 2, d-fetch, returned HTTP 429 (too many requests). Tier 3, d-proxy-1, loaded examine.com/search/?q=losartan, which stated "Sorry, there are no search results for losartan." Tier 4, d-proxy-2, was not needed. -->

No Examine article on losartan exists. Examine.com does not typically cover prescription medications.

  
## ConsumerLab

<!-- Search statement: consumerlab.com was searched directly on 2026-10-16. Tier 1, d-browser, loaded consumerlab.com/search/?q=losartan; tier 2, d-fetch, returned the same result list. The results contained only reviews of other products (potassium, quercetin and rutin, berberine, elderberry supplements) and general interaction answers in which losartan appears in passing; there is no dedicated losartan article. -->

No ConsumerLab article on losartan exists. ConsumerLab does not typically cover prescription medications.

  
## Systematic Reviews

Systematic reviews and meta-analyses covering losartan's blood pressure effect, tolerability, mortality relative to related drugs, aortic protection, and uric-acid lowering.

<!-- Search statement: PubMed was searched in real time on 2026-10-16 for losartan with "systematic review OR meta-analysis" (title search: 28 records; full search: 96 records). Selection prioritized citation impact (Cochrane and Lancet/European Heart Journal publications), size, recency, and relevance to health-focused adults, and included reviews on both the claimed effects and the principal trade-offs. -->

* [Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension.](https://pubmed.ncbi.nlm.nih.gov/18843650/) - Heran et al., 2008

  Cochrane review of 46 placebo-controlled trials: angiotensin receptor blockers (drugs blocking angiotensin II's main receptor), including losartan, lower end-of-dose pressure about 8/5 mmHg.

* [Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension.](https://pubmed.ncbi.nlm.nih.gov/25148386/) - Li et al., 2014

  Cochrane head-to-head review: ACE inhibitors (drugs blocking angiotensin II production) and angiotensin receptor blockers had similar mortality; blockers caused fewer adverse-effect withdrawals.

* [Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients.](https://pubmed.ncbi.nlm.nih.gov/22511654/) - van Vark et al., 2012

  Pooled 20 hypertension outcome trials: ACE inhibitors reduced all-cause death whereas angiotensin receptor blockers as a class did not, a key forgone-benefit question.

* [Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials.](https://pubmed.ncbi.nlm.nih.gov/36049495/) - Pitcher et al., 2022

  In Marfan syndrome (an inherited connective-tissue disorder), angiotensin receptor blockers, mainly losartan, roughly halved yearly enlargement of the aortic root (main artery's base).

* [Urate-lowering effects of losartan: a meta-analysis of randomised controlled trials and target trial emulation.](https://pubmed.ncbi.nlm.nih.gov/42458015/) - Xu et al., 2026

  Six placebo-controlled trials quantify losartan's distinctive uric-acid-lowering effect, about 0.3 mg/dL, confirmed in a UK Biobank analysis.

Losartan-specific systematic reviews of its principal harms (high blood potassium, fetal injury) were not found; tolerability is represented by Li et al., 2014.

  
## Mechanism of Action

Losartan selectively blocks the angiotensin II type 1 (AT1) receptor, through which angiotensin II, the central hormone of the renin-angiotensin-aldosterone system (RAAS, the hormone cascade regulating blood pressure, salt, and fluid), narrows arteries, releases aldosterone (a hormone that makes the kidneys retain salt and excrete potassium), and drives inflammation and TGF-β-mediated scarring. Blocking AT1 relaxes arteries, lowers pressure inside the kidney's filters, and reduces protein leakage into urine.

* **Selectivity:** About 1000-fold greater affinity for AT1 than for the AT2 receptor (a second angiotensin receptor thought to counter AT1 effects), with no partial activation ([product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39)).
* **Metabolism:** About 33% oral bioavailability (share of a dose reaching the bloodstream); roughly 14% of a dose is converted by CYP2C9 (a liver enzyme that processes many drugs) and CYP3A4 (another major drug-processing liver enzyme) to E-3174, a metabolite 10–40 times more potent that supplies most of the effect.
* **Half-life:** About 2 hours for losartan and 6–9 hours for E-3174.
* **Distribution:** Over 98% bound to albumin (the main blood protein); in rats it crosses the blood-brain barrier poorly.
* **Uric acid:** The parent drug inhibits URAT1 (a kidney transporter that reabsorbs uric acid), a mild uric-acid-lowering action most related drugs lack.

Competing explanations exist. Supporters attribute stroke, kidney, and heart-rhythm benefits to effects beyond blood pressure, such as less scarring and unopposed AT2 signaling; skeptics note that comparators like atenolol are weak and that most benefit tracks blood pressure lowering. The TGF-β explanation from Marfan mice translated only partly to people.

  
## Historical Context & Evolution

Losartan (code name DuP 753) was synthesized at DuPont in 1986 as the first orally active AT1 receptor blocker, building on earlier compounds from Takeda. Co-developed with Merck, it was approved by the US Food and Drug Administration (FDA) in 1995 as Cozaar for hypertension ([product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39)). Its intended advantage over ACE inhibitors was blocking angiotensin II directly without the buildup of bradykinin (a vessel-widening peptide) that causes the ACE-inhibitor dry cough.

Large Merck-funded outcome trials followed. One showed slower kidney decline in type 2 diabetic kidney disease ([Brenner et al., 2001](https://pubmed.ncbi.nlm.nih.gov/11565518/)), and another showed fewer strokes than atenolol-based treatment ([Dahlöf et al., 2002](https://pubmed.ncbi.nlm.nih.gov/11937178/)); both led to new labeled uses ([product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39)). Not every early signal held: a hint of better survival than captopril in older heart failure patients was not confirmed in a larger trial ([Pitt et al., 2000](https://pubmed.ncbi.nlm.nih.gov/10821361/)).

Interest beyond blood pressure grew when Johns Hopkins researchers showed losartan prevented aortic aneurysm (a dangerous bulging of the main artery) in Marfan mice by damping TGF-β ([Habashi et al., 2006](https://pubmed.ncbi.nlm.nih.gov/16601194/)). Human trials then gave mixed results until a pooled analysis found a modest effect ([Pitcher et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36049495/)). Longevity interest followed the finding that mice lacking the AT1 receptor live longer ([Benigni et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19197138/)). Later, nitrosamine contamination recalls of some generic lots in 2018–2019 raised manufacturing-quality questions ([FDA, 2019](https://www.fda.gov/news-events/press-announcements/fda-provides-update-its-ongoing-investigation-arb-drug-products-reports-finding-new-nitrosamine)). The receptor-longevity link remains established in mice but untested as a human lifespan outcome.

  
## Expected Benefits

<!-- Search statement: Before writing this section, a dedicated search of the complete benefit profile was run on 2026-10-16 using PubMed (losartan with outcome terms: blood pressure, kidney, stroke, diabetes, atrial fibrillation, heart failure, Marfan, uric acid, gout, dementia, Alzheimer, muscle, mobility, lifespan, aging, mitochondria, fatty liver, cancer), the FDA product label (DailyMed), and expert sources (Grokipedia, peterattiamd.com, de Cavanagh reviews). The search specifically looked for trials of any design that found no effect or the opposite effect (ELITE II, OPTIMAAL, Marfan Sartan, Pediatric Heart Network, RADAR, ENRGISE, pooled mortality analyses). -->

### High 🟩 🟩 🟩

#### Blood Pressure Reduction

Losartan lowers blood pressure by blocking angiotensin II's vessel-narrowing and salt-retaining actions. A placebo-controlled trial by Weber and colleagues using ambulatory monitoring (a portable cuff taking readings around the clock) confirmed 24-hour lowering at 50 mg once daily, and a Cochrane review by Heran and colleagues found no meaningful differences among drugs in the class. A French placebo-controlled trial by Milleron and colleagues ([Milleron et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25935877/)) also recorded about 5 mmHg lower pressure. Average reductions are moderate, so many users need a second drug.

**Magnitude:** 24-hour ambulatory pressure fell 9.2/6.9 mmHg on 50 mg once daily and 13.2/8.5 mmHg on 50 mg twice daily versus 0.0/0.2 mmHg on placebo, all doses differing significantly from placebo; no confidence interval reported ([Weber et al., 1995](https://pubmed.ncbi.nlm.nih.gov/7848024/)). Across the class, placebo-subtracted end-of-dose lowering averaged about 8/5 mmHg ([Heran et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18843650/)).

#### Slower Kidney Disease Progression

Blocking angiotensin II relaxes the outflow vessel of the kidney's filtering units, lowering filtration pressure and proteinuria (protein leaking into urine); creatinine, a blood waste marker, gauges kidney function. In the Merck-funded RENAAL trial led by Brenner, losartan slowed kidney decline in 1,513 people with type 2 diabetes and kidney disease, beyond what blood pressure explained. In non-diabetic kidney disease, the independent ROAD trial by Hou found proteinuria-guided dosing outperformed a fixed 50 mg dose. RENAAL showed no effect on death.

**Magnitude:** Versus placebo, losartan lowered the risk of the composite of doubled creatinine, end-stage renal disease (kidney failure needing dialysis or transplant), or death by 16% (327 vs 359 patients), doubled creatinine by 25%, end-stage renal disease by 28%, and proteinuria by 35% ([Brenner et al., 2001](https://pubmed.ncbi.nlm.nih.gov/11565518/)). Proteinuria-guided dosing cut the composite risk by 53% versus 50 mg daily ([Hou et al., 2007](https://pubmed.ncbi.nlm.nih.gov/17494885/)).

### Medium 🟩 🟩

#### Fewer Strokes Than Atenolol-Based Treatment

In the Merck-funded LIFE trial of 9,193 adults aged 55–80 with hypertension and left ventricular hypertrophy, losartan-based treatment produced fewer strokes and fewer combined cardiovascular events than atenolol-based treatment despite nearly identical blood pressure reductions. The comparison is against an active drug rather than placebo, and atenolol is regarded as a weak comparator, so part of the gap may reflect atenolol's shortcomings. The [product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39) notes the benefit may not apply to Black patients. Heart attacks were not reduced.

**Magnitude:** Stroke: relative risk (RR, the ratio of event rates between groups) 0.75, 95% confidence interval (CI, the range likely to contain the true effect) 0.63–0.89; 232 vs 309 patients. Composite of cardiovascular death, heart attack, or stroke: RR 0.87 (95% CI 0.77–0.98); 23.8 vs 27.9 events per 1,000 patient-years (events per 1,000 people followed for one year) ([Dahlöf et al., 2002](https://pubmed.ncbi.nlm.nih.gov/11937178/)).

#### Greater Regression of Thickened Heart Muscle

In the LIFE echocardiography (heart ultrasound) substudy led by Devereux, losartan-based treatment reduced left ventricular mass (the bulk of the heart's main pumping chamber, which thickens under high pressure and predicts heart attacks and strokes) more than atenolol-based treatment, after adjustment for blood pressure. The advantage held in women and men and in people above and below 65. The evidence comes from a single Merck-funded active-comparator trial.

**Magnitude:** Left ventricular mass index fell 21.7 g/m² with losartan versus 17.7 g/m² with atenolol, a statistically significant difference; the abstract reports no between-group difference or confidence interval ([Devereux et al., 2004](https://pubmed.ncbi.nlm.nih.gov/15326072/)).

#### Lower Risk of New-Onset Diabetes

Among 7,998 LIFE participants without diabetes at entry, fewer developed diabetes on losartan than on atenolol at every level of baseline risk. Because beta-blockers can themselves raise diabetes risk, part of the difference may reflect harm from the comparator rather than protection from losartan. The evidence comes from this single active-comparator trial.

**Magnitude:** RR 0.75 (95% CI 0.63–0.88); 13.0 vs 17.5 new cases per 1,000 person-years ([Lindholm et al., 2002](https://pubmed.ncbi.nlm.nih.gov/12195132/)).

#### Lower Risk of Atrial Fibrillation

Atrial fibrillation (an irregular heart rhythm that raises stroke risk) developed less often on losartan than on atenolol among 8,851 LIFE participants free of it at entry, despite similar blood pressure control. Proposed mechanisms include less scarring and stretching of the upper heart chambers. As with the stroke finding, the comparator is an active drug in a single trial.

**Magnitude:** RR 0.67 (95% CI 0.55–0.83); 6.8 vs 10.1 new cases per 1,000 person-years ([Wachtell et al., 2005](https://pubmed.ncbi.nlm.nih.gov/15734615/)).

#### Fewer Heart Failure Hospitalizations ⚠️ Conflicted

In heart failure, the Merck-funded HEAAL trial led by Konstam found 150 mg daily reduced death or heart failure admission versus 50 mg, and RENAAL (Brenner) found fewer first heart failure hospitalizations versus placebo. However, losartan 50 mg did not match the ACE inhibitor captopril on survival in ELITE II (Pitt) or after heart attack in OPTIMAAL ([Dickstein et al., 2002](https://pubmed.ncbi.nlm.nih.gov/12241832/)), which showed a non-significant trend favoring captopril. Net reading: losartan reduces heart failure admissions at adequate doses but has not matched ACE inhibitors on survival.

**Magnitude:** Death or heart failure admission, 150 vs 50 mg: hazard ratio (HR, the relative event rate over time) 0.90 (95% CI 0.82–0.99); 43% vs 46% of patients ([Konstam et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19922995/)). First heart failure hospitalization versus placebo: 32% lower risk ([Brenner et al., 2001](https://pubmed.ncbi.nlm.nih.gov/11565518/)). All-cause death versus captopril: HR 1.13 (95.7% CI 0.95–1.35) ([Pitt et al., 2000](https://pubmed.ncbi.nlm.nih.gov/10821361/)).

#### Slower Aortic Root Enlargement in Marfan Syndrome ⚠️ Conflicted

An individual-patient meta-analysis by Pitcher and colleagues found angiotensin receptor blockers, mostly losartan, roughly halved yearly aortic-root enlargement versus control, including on top of beta-blockers. Single trials disagreed: the French placebo-controlled trial by Milleron ([Milleron et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25935877/)) found no slowing, and the Pediatric Heart Network trial by Lacro ([Lacro et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25405392/)) found no significant difference from atenolol. Smaller size, different ages, and Lacro's active atenolol comparator likely explain this. Net reading: modest slowing, not yet shown to prevent dissection (a tear in the aortic wall) or surgery.

**Magnitude:** Yearly increase in body-size-adjusted aortic-root score 0.07 with angiotensin receptor blockers vs 0.13 with control; difference −0.07 (95% CI −0.12 to −0.01) ([Pitcher et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36049495/)).

#### Lower Uric Acid and Gout Risk

Unlike most drugs in its class, losartan increases uric acid excretion by blocking the kidney transporter URAT1. A meta-analysis of six randomized trials by Xu and colleagues quantified a small fall in serum urate versus placebo, and a UK case-control study by Choi and colleagues linked current losartan use to fewer new gout cases, while other angiotensin receptor blockers were linked to more. The effect cannot replace dedicated urate-lowering drugs but can offset the urate rise from thiazide diuretics (drugs increasing salt and water excretion).

**Magnitude:** Serum urate −0.29 mg/dL versus placebo (95% CI −0.46 to −0.12) ([Xu et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42458015/)); gout RR 0.81 (95% CI 0.70–0.94) with current use ([Choi et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22240117/)).

### Low 🟩

#### Longer Lifespan ⚠️ Conflicted

Mice lacking the AT1 receptor lived longer ([Benigni et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19197138/)), but deleting the receptor gene differs from taking the drug. Pooling 20 hypertension trials, angiotensin receptor blockers as a class (not losartan alone) did not lower all-cause death. Net reading: no human evidence of longer life.

**Magnitude:** All-cause death with angiotensin receptor blockers versus control: HR 0.99 (95% CI 0.94–1.04) ([van Vark et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22511654/)).

#### Dementia Prevention ⚠️ Conflicted

A large US veterans cohort linked angiotensin receptor blocker use to less dementia, but these class-level observational data are indirect. In the RADAR trial, 12 months of losartan 100 mg did not slow brain shrinkage in mild-to-moderate Alzheimer's disease. Net reading: prevention remains unproven.

**Magnitude:** Brain volume loss, losartan vs placebo: difference −2.29 mL (95% CI −6.46 to 0.89), not significant ([Kehoe et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34687634/)); class-level incident dementia HR 0.76 (95% CI 0.69–0.84) versus other cardiovascular drugs ([Li et al., 2010](https://pubmed.ncbi.nlm.nih.gov/20068258/)).

#### Muscle Preservation and Mobility in Older Adults ⚠️ Conflicted

Losartan restored muscle repair in mouse models ([Cohn et al., 2007](https://pubmed.ncbi.nlm.nih.gov/17237794/)). In the ENRGISE pilot (adults 70 or older), losartan did not improve walking speed or IL-6 (interleukin-6, an inflammation signal). A 25-person pilot in prefrail (early-frailty) adults reported less frailty. Net reading: unproven.

**Magnitude:** 400-meter walking speed, losartan vs placebo: −0.025 m/s (95% CI −0.076 to 0.026), not significant ([Pahor et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30541065/)); frailty score 0.3 points lower than placebo (95% CI 0.01–0.5) ([Lee et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35511890/)).

#### Pancreatic Cancer Treatment Add-On

In a single-arm phase 2 trial, losartan was added to FOLFIRINOX chemotherapy (a four-drug regimen) and radiation for locally advanced pancreatic cancer to loosen tumor scar tissue. Losartan was never tested alone or against the same regimen without it, so its contribution is unknown (indirect evidence).

**Magnitude:** Complete removal with tumor-free margins (R0 resection) in 34 of 49 patients (69%; 95% CI 55%–82%); median overall survival 31.4 months; no control group ([Murphy et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31145418/)).

### Speculative 🟨

#### Protection of Mitochondrial Function With Aging

In aged rats, eight months of losartan preserved kidney mitochondrial function and lowered oxidant production ([de Cavanagh et al., 2003](https://pubmed.ncbi.nlm.nih.gov/12709417/)). The basis is animal data only.

#### Liver Enzyme Improvement in Fatty Liver Disease

Six small trials linked losartan to lower ALT and AST (enzymes released by damaged liver cells) in fatty liver disease ([Meng et al., 2023](https://pubmed.ncbi.nlm.nih.gov/36970603/)). These are unvalidated markers; no liver outcome benefit is shown.

  
## Benefit-Modifying Factors

* **CYP2C9 variants:** Carriers of the reduced-function CYP2C9*2 or *3 variants form less of the potent metabolite E-3174 ([Park et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34210056/)), which may blunt blood pressure response; the [product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39) gives no genotype-based dosing.
* **Ancestry:** In LIFE, Black participants fared better on atenolol than on losartan for the main composite outcome, and the label states the stroke benefit may not apply to Black patients ([product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39)).
* **Baseline biomarkers:** Higher baseline blood pressure, proteinuria, and uric acid leave more room for benefit. A low-sodium diet nearly doubled losartan's proteinuria reduction ([Vogt et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18272844/)); high potassium intake blunted it ([Wouda et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34603695/)).
* **Sex:** Women reach about twice the plasma losartan levels of men, with similar active-metabolite levels, and the [product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39) sets no sex-based dose change; LIFE enrolled 54% women ([Lindholm et al., 2002](https://pubmed.ncbi.nlm.nih.gov/12195132/)), so its outcome data apply to both sexes.
* **Pre-existing conditions:** Outcome benefits were shown in diabetic or proteinuric kidney disease, left ventricular hypertrophy, heart failure, and Marfan syndrome; no outcome trial exists in low-risk adults with normal blood pressure, where the expected absolute benefit is smaller.
* **Age:** Trials enrolled mainly middle-aged and older adults (LIFE ages 55–80). In adults over 70 ([Pahor et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30541065/)) and in Alzheimer's disease ([Kehoe et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34687634/)), losartan showed no functional or brain benefit, so aging-specific gains remain unproven.

  
## Potential Risks & Side Effects

<!-- Search statement: Before writing this section, a dedicated search of the complete side-effect profile was run on 2026-10-16 using the FDA prescribing information for Cozaar (DailyMed, revised 6/2025), FDA recall announcements, and PubMed (losartan with hyperkalemia, hypotension, renal function, angioedema, pregnancy/fetopathy, cancer, nitrosamine, cough, muscle). The search specifically looked for studies of any design that found no excess risk or a lower risk (ARB Trialists cancer analysis, angioedema meta-analysis versus placebo, label cough-challenge trials, Danish nitrosamine cohort). -->

### High 🟥 🟥 🟥

#### Hyperkalemia (High Blood Potassium)

By lowering aldosterone, losartan raises blood potassium; severe elevations can trigger dangerous heart rhythms. In a post hoc (after-the-fact) analysis of RENAAL by Miao and colleagues, elevations were about twice as common as with placebo and linked to faster kidney decline. In HEAAL (Konstam), hyperkalemia rose with dose. Risk concentrates in kidney disease, diabetes, older age, and with potassium supplements or potassium-retaining drugs; in uncomplicated hypertension the label reports very little effect on potassium ([product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39)).

**Magnitude:** Serum potassium ≥5.5 mmol/L at 6 months in 10.8% on losartan vs 5.1% on placebo ([Miao et al., 2011](https://pubmed.ncbi.nlm.nih.gov/20882268/)); hyperkalemia in 195 of 1,927 patients on 150 mg vs 131 of 1,919 on 50 mg ([Konstam et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19922995/)).

### Medium 🟥 🟥

#### Low Blood Pressure and Dizziness

Excess lowering can cause dizziness, light-headedness, fainting, and orthostatic hypotension (a blood pressure drop on standing), especially with dehydration, diuretics, or higher doses. In placebo-controlled hypertension trials summarized in the label, dizziness was only slightly more common than with placebo. In HEAAL (Konstam), hypotension was more frequent at 150 mg than at 50 mg. Older adults face added fall risk.

**Magnitude:** Dizziness 3% vs 2% on placebo ([product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39)); hypotension in 203 of 1,927 patients on 150 mg vs 145 of 1,919 on 50 mg ([Konstam et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19922995/)).

#### Kidney Function Decline

Angiotensin II maintains filtration pressure when kidney blood flow is low, so blocking it can cause an abrupt fall in filtration, particularly with renal artery stenosis (narrowed kidney arteries), dehydration, heart failure, or NSAIDs (non-steroidal anti-inflammatory drugs such as ibuprofen). In HEAAL (Konstam), renal impairment was more frequent at 150 mg than at 50 mg. A modest early creatinine rise is expected and is often reversible.

**Magnitude:** Renal impairment in 454 of 1,927 patients on 150 mg vs 317 of 1,919 on 50 mg ([Konstam et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19922995/)).

#### Lower Hemoglobin (Anemia)

Angiotensin II stimulates red blood cell production, so blocking it modestly lowers hemoglobin; the effect is used to treat post-transplant erythrocytosis (excess red cells after kidney transplant). In a post hoc RENAAL analysis by Mohanram and colleagues, losartan lowered hemoglobin versus placebo, while kidney protection persisted. Julian and colleagues documented dose-related falls in hematocrit (the red-cell share of blood) that reversed after stopping. People with borderline anemia, or athletes tracking hemoglobin, may notice the drop.

**Magnitude:** Hematocrit fell from 52.7% to 48.7% after 8 weeks; no control group ([Julian et al., 1998](https://pubmed.ncbi.nlm.nih.gov/9621296/)). Versus placebo, hemoglobin fell significantly, most at 1 year, but the abstract reports no figure ([Mohanram et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18094675/)).

### Low 🟥

#### Fetal Injury and Death

Renin-angiotensin blockers impair fetal kidneys after week 20, causing oligohydramnios (low amniotic fluid), lung underdevelopment, and fetal or newborn death; the [product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39) carries a boxed warning. A cohort pooling several angiotensin receptor blockers (class-level, indirect for losartan) found fetopathy (drug-induced fetal organ damage) far more often than ACE inhibitors.

**Magnitude:** Fetopathy after exposure beyond 20 weeks: 29.2% with angiotensin receptor blockers vs 3.2% with ACE inhibitors among prospectively enrolled pregnancies; no unexposed control group ([Weber-Schoendorfer et al., 2020](https://pubmed.ncbi.nlm.nih.gov/31568057/)).

#### Cancer ⚠️ Conflicted

A 2010 meta-analysis by Sipahi and colleagues, dominated by telmisartan trials, reported slightly more new cancers with angiotensin receptor blockers. A larger analysis of 15 trials (138,769 participants), including the losartan LIFE trial, found no excess overall or for individual drugs. Net reading: no reliable cancer signal for losartan.

**Magnitude:** New cancer RR 1.08 (95% CI 1.01–1.15), 7.2% vs 6.0% ([Sipahi et al., 2010](https://pubmed.ncbi.nlm.nih.gov/20542468/)), versus odds ratio (OR, the ratio of the odds of an event) 1.00 (95% CI 0.95–1.04), 6.16% vs 6.31% ([ARB Trialists Collaboration, 2011](https://pubmed.ncbi.nlm.nih.gov/21358417/)).

#### Angioedema ⚠️ Conflicted

Angioedema (sudden deep swelling of the face, lips, tongue, or throat) appears in postmarketing reports. A meta-analysis of randomized trials by Makani and colleagues found class-level rates (indirect for losartan) not significantly above placebo. Net reading: rare, and less frequent than with ACE inhibitors.

**Magnitude:** Weighted incidence 0.11% (95% CI 0.09–0.13) with angiotensin receptor blockers vs 0.07% (95% CI 0.05–0.09) with placebo and 0.30% with ACE inhibitors ([Makani et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22521308/)).

#### Nitrosamine Impurity Exposure

In 2019, some generic losartan lots were recalled for NMBA (N-nitroso-N-methyl-4-aminobutyric acid, a potential human carcinogen) ([FDA, 2019](https://www.fda.gov/news-events/press-announcements/fda-provides-update-its-ongoing-investigation-arb-drug-products-reports-finding-new-nitrosamine)). Cancer data exist only for contaminated valsartan, a related drug (indirect evidence).

**Magnitude:** Overall cancer with valsartan contaminated by NDMA (N-nitrosodimethylamine, a related nitrosamine and probable human carcinogen): HR 1.09 (95% CI 0.85–1.41) versus uncontaminated use ([Pottegård et al., 2018](https://pubmed.ncbi.nlm.nih.gov/30209057/)).

### Speculative 🟨

#### Blunted Muscle Growth From Strength Training

In rats, an AT1 receptor blocker reduced overload-induced muscle growth by about half ([Gordon et al., 2001](https://pubmed.ncbi.nlm.nih.gov/11120669/)). The basis is animal data only; no human resistance-training trial of losartan was found.

  
## Risk-Modifying Factors

* **CYP2C9 variants:** CYP2C9*2 or *3 carriers keep more parent losartan and form less E-3174 ([Park et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34210056/)); no variant-specific safety signal is established.
* **Baseline potassium and kidney function:** Higher starting potassium and lower eGFR (estimated glomerular filtration rate, the kidneys' filtering capacity) raise hyperkalemia and kidney-injury risk ([product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39)).
* **Sex:** The dominant sex-specific risk is fetal injury for women who could become pregnant; women also reach about twice the plasma losartan levels of men, without a dose change in the [product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39).
* **Pre-existing conditions:** Chronic kidney disease, diabetes, heart failure, renal artery stenosis, liver impairment (about 5-fold losartan and 1.7-fold active-metabolite levels in cirrhosis), and volume depletion increase risks of hyperkalemia, kidney injury, or hypotension ([product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39)).
* **Age:** Drug levels are similar in older and younger adults ([product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39)), but older users more often have reduced kidney function, take interacting drugs, and fall from orthostatic hypotension.

  
## Key Interactions & Contraindications

<!-- Search statement: Before writing this section, PubMed was searched on 2026-10-16 for losartan with "drug interaction" OR "pharmacokinetics" (including fluconazole, rifampin, erythromycin, grapefruit, silymarin/milk thistle, lisinopril dual blockade, trimethoprim-sulfamethoxazole), and the FDA label's drug-interaction section was reviewed. Human pharmacokinetic studies were used where they exist; mechanism-only interactions are marked (theoretical). -->

**Prescription drugs**

* **Potassium-sparing diuretics and aldosterone blockers (spironolactone, eplerenone, amiloride, triamterene):** Caution — additive potassium retention can cause hyperkalemia; the label lists agents that raise potassium ([product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39)). An early potassium check after combining detects it.
* **ACE inhibitors (lisinopril, enalapril, ramipril):** Avoid — adding lisinopril to losartan raised hyperkalemia (6.3 vs 2.6 events per 100 person-years) and acute kidney injury without benefit ([Fried et al., 2013](https://pubmed.ncbi.nlm.nih.gov/24206457/)).
* **Aliskiren (a direct renin inhibitor; renin is the kidney enzyme that starts angiotensin production):** Contraindicated in diabetes and to be avoided when glomerular filtration rate (GFR) is below 60 mL/min — dual blockade increases hypotension, fainting, hyperkalemia, and kidney impairment ([product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39)).
* **Lithium:** Monitor — reduced lithium clearance risks lithium toxicity (tremor, confusion); the label calls for lithium level monitoring during combined use ([product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39)).
* **Rifampin:** Monitor — lowered exposure to losartan by 35% and to E-3174 by 40%, which may weaken blood pressure control; erythromycin showed no meaningful interaction in the same study ([Williamson et al., 1998](https://pubmed.ncbi.nlm.nih.gov/9542475/)). Home readings detect loss of control.
* **Fluconazole (a CYP2C9 inhibitor):** Monitor — raised losartan exposure 66% but cut E-3174 exposure 43% ([Kazierad et al., 1997](https://pubmed.ncbi.nlm.nih.gov/9357393/)); the net blood pressure effect is untested, so home readings help.
* **Trimethoprim-sulfamethoxazole (co-trimoxazole, an antibiotic):** Caution — in adults 66 or older on renin-angiotensin blockers, it raised hyperkalemia hospitalization versus amoxicillin ([Antoniou et al., 2010](https://pubmed.ncbi.nlm.nih.gov/20585070/)) and sudden death ([Fralick et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25359996/)); an alternative antibiotic or early potassium check limits risk.
* **Other blood pressure-lowering drugs (amlodipine, hydrochlorothiazide, metoprolol):** Monitor — additive lowering can cause dizziness or fainting; hydrochlorothiazide 12.5 mg added to losartan produced further, clinically meaningful lowering ([Weber et al., 1995](https://pubmed.ncbi.nlm.nih.gov/7848024/)); adding one drug at a time with seated and standing home readings limits this.
* **PDE5 inhibitors (erectile dysfunction drugs that widen vessels: sildenafil, tadalafil), alpha-blockers (vessel-relaxing drugs: tamsulosin, doxazosin):** Monitor (theoretical) — additive lowering can cause dizziness or fainting; starting at the lowest dose and taking alpha-blockers at bedtime limit this.

**Over-the-counter medications**

* **NSAIDs including COX-2 inhibitors (selective anti-inflammatories: ibuprofen, naproxen, celecoxib):** Caution — acute kidney injury risk ([product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39)); indomethacin blunted 24-hour diastolic lowering by 2.2 mmHg ([Conlin et al., 2000](https://pubmed.ncbi.nlm.nih.gov/10988282/)); a small crossover trial found no blunting ([Olsen et al., 1999](https://pubmed.ncbi.nlm.nih.gov/10090350/)). Acetaminophen avoids both.
* **Potassium-containing salt substitutes (potassium chloride "lite" salts):** Caution — hyperkalemia; the label advises against them without medical oversight ([product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39)).
* **Decongestants (pseudoephedrine, phenylephrine):** Monitor (theoretical) — they raise blood pressure and may offset losartan's effect; short courses with home readings limit the impact.

**Supplements**

* **Potassium supplements:** Caution — hyperkalemia, particularly with reduced kidney function ([product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39)); a potassium check after starting one detects it early.
* **Milk thistle (silymarin):** Monitor — silymarin reduced conversion of losartan to E-3174, more in CYP2C9*1/*1 carriers ([Han et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19221727/)), so blood pressure lowering may weaken; home readings when starting it detect this.
* **Grapefruit juice:** Monitor — modestly reduced E-3174 exposure ([Zaidenstein et al., 2001](https://pubmed.ncbi.nlm.nih.gov/11477318/)); clinical impact is likely small.
* **Blood pressure-lowering supplements (garlic extract, beetroot nitrate, magnesium, coenzyme Q10, fish oil, hibiscus):** Monitor (theoretical) — additive lowering may cause dizziness; home readings when adding one detect excess lowering.
* **Licorice root (glycyrrhizin):** Caution (theoretical) — mimics aldosterone, raising blood pressure and lowering potassium, which opposes losartan's effect; limiting licorice intake avoids this.
* **St John's wort:** Monitor (theoretical) — induces drug-metabolizing liver enzymes and could alter losartan activation and blood pressure control; home readings when starting or stopping it detect changes.

**Other interventions**

* **Alcohol:** Monitor (theoretical) — additive vessel relaxation increases dizziness and fainting, especially when standing quickly; moderate intake and rising slowly limit this.
* **Heat, sauna, prolonged endurance exercise, or fluid loss:** Caution — volume depletion increases hypotension and kidney injury risk; the label advises correcting volume depletion before starting ([product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39)).

**Populations who should avoid Losartan:**

* Pregnancy at any stage; the label directs stopping as soon as pregnancy is detected (boxed warning, [product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39))
* People with diabetes who take aliskiren (label contraindication, [product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39))
* Hypersensitivity to any component of the product (label contraindication, [product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39))
* Breastfeeding, unless the importance of the drug outweighs nursing ([product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39))
* Severe hepatic impairment, in which losartan has not been studied ([product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39))
* Children under 6 years, or children with GFR below 30 mL/min/1.73 m² (not recommended, [product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39))
* Prior angioedema during angiotensin receptor blocker use (postmarketing angioedema reports, [product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39))

  
## Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

* **Pregnancy prevention:** Confirming non-pregnancy before starting, reliable contraception, and stopping losartan as soon as pregnancy is detected prevent fetal kidney injury ([product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39)).
* **Early blood checks:** Kidney Disease: Improving Global Outcomes (KDIGO), whose authors earn no direct revenue from generic losartan, advises potassium and creatinine checks within 2–4 weeks of starting or raising the dose ([KDIGO 2021](https://pubmed.ncbi.nlm.nih.gov/33637192/)), catching hyperkalemia early.
* **Creatinine threshold:** KDIGO (no direct revenue from losartan) advises continuing unless creatinine rises more than 30% within 4 weeks ([KDIGO 2021](https://pubmed.ncbi.nlm.nih.gov/33637192/)); larger rises warrant review, preventing progressive kidney injury.
* **Potassium sources:** Leaving out potassium supplements and potassium-based salt substitutes, unless potassium is being monitored, prevents hyperkalemia.
* **Sick-day pause:** A temporary hold during vomiting, diarrhea, or poor fluid intake, resuming once eating and drinking return to normal, reduces acute kidney injury and hypotension risk.
* **Low start when volume-depleted or with liver impairment:** The labeled starting dose in these situations is 25 mg once daily ([product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39)) to reduce first-dose hypotension.
* **NSAID avoidance:** Acetaminophen for pain, or a short NSAID course with a creatinine check when one is necessary, prevents kidney injury and loss of blood pressure control.
* **Gradual standing and home readings:** Rising slowly and logging seated and standing home readings during the first 2–4 weeks of titration (stepwise dose adjustment) prevent falls from orthostatic hypotension.
* **Angioedema plan:** Stopping the drug and emergency care for swelling of lips, tongue, or throat, with no restart of any angiotensin receptor blocker without specialist review, prevent airway compromise.
* **Lot checking:** Comparing manufacturer and lot number with FDA recall listings avoids nitrosamine-contaminated product.

  
## Therapeutic Protocol

Each dose below is cited to its source; other parameters without a citation (timing, titration steps, splitting) reflect common practice.

* **Hypertension (product label):** Start 50 mg once daily, increasing to a maximum of 100 mg once daily; start 25 mg with possible volume depletion or liver impairment ([product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39)).
* **Hypertension with thickened heart muscle (LIFE regimen):** 50 mg once daily, adding hydrochlorothiazide 12.5 mg and/or increasing losartan to 100 mg as needed ([Dahlöf et al., 2002](https://pubmed.ncbi.nlm.nih.gov/11937178/)).
* **Diabetic kidney disease (RENAAL regimen):** 50 mg once daily, increased to 100 mg after about a month if blood pressure requires ([Brenner et al., 2001](https://pubmed.ncbi.nlm.nih.gov/11565518/)).
* **Proteinuria-guided up-titration (Hou, ROAD trial):** Dose raised against proteinuria to a median 100 mg (range 50–200 mg) daily, beyond the US labeled maximum, with better kidney outcomes than 50 mg ([Hou et al., 2007](https://pubmed.ncbi.nlm.nih.gov/17494885/)).
* **Heart failure (HEAAL regimen, Konstam):** 150 mg daily outperformed 50 mg for death or heart failure admission, with more hyperkalemia and hypotension ([Konstam et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19922995/)).
* **Marfan syndrome (approach popularized by Harry Dietz, Johns Hopkins):** After mouse work ([Habashi et al., 2006](https://pubmed.ncbi.nlm.nih.gov/16601194/)), an adult-adolescent trial used 50 mg under 50 kg and 100 mg otherwise ([Milleron et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25935877/)).
* **Longevity-oriented use:** No trial has tested losartan for lifespan in healthy adults with normal blood pressure, and no practitioner protocol was found; aging researchers propose trials, even at subclinical doses ([de Cavanagh et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38924381/)).
* **Time of day:** Evening versus morning dosing of usual antihypertensives made no difference to cardiovascular events ([Mackenzie et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36240838/)); an earlier trial reporting bedtime benefit ([Hermida et al., 2020](https://pubmed.ncbi.nlm.nih.gov/31641769/)) received a journal [expression of concern](https://pubmed.ncbi.nlm.nih.gov/32318736/). Consistent timing matters most.
* **Half-life:** About 2 hours for losartan and 6–9 hours for E-3174, supporting once-daily dosing for most users ([product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39)).
* **Single versus split dose:** 50 mg twice daily lowered 24-hour ambulatory pressure more than 50 mg once daily and similarly to 100 mg once daily ([Weber et al., 1995](https://pubmed.ncbi.nlm.nih.gov/7848024/)); splitting may help if evening readings rise.
* **Genetic polymorphisms:** CYP2C9*2 or *3 carriers form less E-3174 ([Park et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34210056/)); with no genotype dosing in the [product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39), titration follows home blood pressure.
* **Sex:** Women reach about double the parent-drug levels with similar metabolite levels, and the [product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39) sets no sex-based dose change; contraception planning precedes use in women who could conceive.
* **Age:** No age-based dose adjustment is labeled; older adults with possible volume depletion start at the labeled 25 mg ([product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39)) and titrate every 2–4 weeks to limit orthostatic hypotension.
* **Baseline biomarkers:** Baseline blood pressure, potassium, creatinine/eGFR, urine albumin, and uric acid inform starting dose and titration; high potassium or reduced eGFR favor lower starting doses and closer checks.
* **Pre-existing conditions:** Liver impairment: 25 mg start ([product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39)); heart failure: titration toward 150 mg ([Konstam et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19922995/)); diabetic or proteinuric kidney disease: titration to 100 mg ([Brenner et al., 2001](https://pubmed.ncbi.nlm.nih.gov/11565518/)) or higher against proteinuria ([Hou et al., 2007](https://pubmed.ncbi.nlm.nih.gov/17494885/)).

  
## Discontinuation & Cycling

* **Intended duration:** Use for hypertension, kidney disease, or heart failure is typically long-term; blood pressure drifts back toward pretreatment levels after stopping.
* **Withdrawal effects:** The label reports no apparent rebound effect after abrupt withdrawal ([product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39)); the main consequence of stopping is loss of blood pressure and kidney protection.
* **Tapering:** Not required pharmacologically; stepwise dose reduction with home blood pressure checks is common practice when deprescribing or switching drugs.
* **Cycling:** No rationale or evidence supports cycling; tolerance is not described, and intermittent use leaves gaps in 24-hour blood pressure control.
* **Mandatory stop:** The label directs discontinuation as soon as pregnancy is detected ([product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39)).
* **Temporary pauses:** Short holds during dehydrating illness or before some surgeries are common practice, resuming once stable.

  
## Sourcing and Quality

* **Prescription status and forms:** Available only by prescription as 25, 50, and 100 mg tablets ([product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39)), sold as brand Cozaar (Organon) and many generics; fixed combinations with hydrochlorothiazide (Hyzaar) or amlodipine also exist.
* **Generic equivalence:** FDA-approved generics must be bioequivalent to the brand ([FDA](https://www.fda.gov/drugs/generic-drugs/generic-drug-facts)); switching manufacturers can change inactive ingredients but not the active dose.
* **Nitrosamine impurities:** Several generic losartan lots were recalled in 2019 for NMBA contamination traced to active-ingredient suppliers ([FDA, 2019](https://www.fda.gov/news-events/press-announcements/fda-provides-update-its-ongoing-investigation-arb-drug-products-reports-finding-new-nitrosamine)); checking manufacturer and lot against FDA recall listings is a practical safeguard.
* **What to look for:** Pharmacies that disclose the generic manufacturer (e.g., Mark Cuban Cost Plus Drug Company) make lot tracking easier; independent batch-testing pharmacies exist but have a commercial interest in highlighting quality problems.
* **Compounding:** Rarely needed; the label describes a pharmacy-prepared 2.5 mg/mL oral suspension for people unable to swallow tablets ([product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39)).
* **Storage:** The label specifies about 25 °C in a tightly closed container, protected from light ([product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39)).

  
## Practical Considerations

* **Time to effect:** Blood pressure lowering is substantially present within one week, with maximal effect at 3–6 weeks in some studies ([product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39)); kidney and cardiovascular outcome benefits emerged over years.
* **Common pitfalls:** Using NSAIDs or potassium salt substitutes, skipping potassium and creatinine checks after dose changes, continuing during dehydrating illness, and assuming losartan equals ACE inhibitors on survival in heart failure.
* **Regulatory status:** FDA-approved for hypertension since 1995 and later also for stroke risk reduction with left ventricular hypertrophy and for diabetic nephropathy (diabetes-related kidney disease) ([product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39)); use for Marfan syndrome, fibrosis (tissue scarring), or longevity is off-label. A boxed fetal-toxicity warning applies.
* **Cost and payer incentives:** Generic losartan is inexpensive, not a cost barrier. Payers favor cheap generics over branded alternatives (e.g., azilsartan, sacubitril/valsartan), and off-patent status deters new sponsored trials, both potential sources of structural bias in research and guidelines.
* **Users with normal blood pressure:** In this group, dizziness and hypotension are more likely, and no outcome benefit has been demonstrated, which shifts the risk-benefit balance.
* **Home monitoring:** A validated upper-arm home monitor makes titration and safety checks practical between clinic visits.

  
## Interaction with Foundational Habits

* **Sleep:** Direction: none to indirect. Losartan has no established direct effect on sleep architecture; lowering nighttime pressure may help people whose pressure fails to dip at night. Evening dosing did not change cardiovascular outcomes ([Mackenzie et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36240838/)). Unlike diuretics, it is not expected to increase nighttime urination.
* **Nutrition:** Direction: potentiating. A low-sodium diet nearly doubled losartan's proteinuria reduction, from 30% to 55% ([Vogt et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18272844/)), while high potassium intake blunted it ([Wouda et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34603695/)). Potassium-rich foods are generally fine with normal kidneys; salt substitutes and supplements raise hyperkalemia risk.
* **Exercise:** Direction: possibly blunting (theoretical). In rats, AT1 blockade reduced overload-induced muscle growth ([Gordon et al., 2001](https://pubmed.ncbi.nlm.nih.gov/11120669/)); human resistance-training data are lacking, and older adults gained no walking speed ([Pahor et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30541065/)). Hydration matters, since heat and heavy sweating amplify dizziness.
* **Stress management:** Direction: indirect. Angiotensin II acts in brain stress circuits, and losartan is under study in post-traumatic stress ([NCT02560805](https://clinicaltrials.gov/study/NCT02560805)) and low mood ([NCT07017023](https://clinicaltrials.gov/study/NCT07017023)), but no proven effect on cortisol or stress resilience exists. Its blood pressure effect complements relaxation practices.

  
## Monitoring Protocol & Defining Success

Baseline testing before starting establishes reference values for safety and response: seated and standing blood pressure measured at home and in clinic, serum potassium, creatinine with eGFR, a urine albumin-to-creatinine ratio (UACR, a measure of protein leaking into urine), serum uric acid, hemoglobin, and a pregnancy test for anyone who could conceive. Success is defined as reaching the blood pressure target without symptomatic hypotension, hyperkalemia, or a large creatinine rise.

Ongoing monitoring follows this cadence: potassium and creatinine within 2–4 weeks of starting or of any dose increase, as advised by KDIGO, whose clinician authors earn no direct revenue from generic losartan ([KDIGO 2021](https://pubmed.ncbi.nlm.nih.gov/33637192/)), again at 3 months, then every 6–12 months; home blood pressure several times weekly during titration and weekly once stable; urine albumin, uric acid, and hemoglobin every 12 months.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|-----------|--------------------------|-----------------|---------------|
| Blood pressure (home, seated) | <130/80 mmHg (ACC/AHA 2017 guideline target) | Expected to change: main treatment effect | Source: [Whelton et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29133356/) (American College of Cardiology/American Heart Association; clinician members earn no direct revenue from generic losartan). Conventional classification: normal <120/80 mmHg (same guideline). Measure after 5 minutes seated, morning and evening. |
| Serum potassium | 3.5–5.0 mmol/L (standard reference range) | Safety check: a rise above range changes dose or use | Check 2–4 weeks after starting or dose change; a difficult or delayed blood draw can falsely raise results; pair with creatinine. |
| Serum creatinine and eGFR | Creatinine about 0.7–1.3 mg/dL in men and 0.6–1.1 mg/dL in women (standard reference range); eGFR: No established target, track change from own baseline | Safety check: a large rise prompts dose review | Track change from own baseline. KDIGO 2021 (authors earn no direct revenue from losartan) advises continuing unless creatinine rises more than 30% within 4 weeks ([KDIGO 2021](https://pubmed.ncbi.nlm.nih.gov/33637192/)). Heavy exercise or a large meat meal in the prior 24 hours can raise creatinine. |
| UACR | <30 mg/g (KDIGO albuminuria category A1) | Expected to change: falls with losartan | Source: [KDIGO 2021](https://pubmed.ncbi.nlm.nih.gov/33637192/) (authors earn no direct revenue from losartan). Conventional laboratory reference: <30 mg/g. First-morning urine sample; repeat abnormal results. |
| Serum uric acid | <6 mg/dL (ACR 2020 gout treat-to-target) | Expected to change: losartan lowers it modestly | Source: [FitzGerald et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32391934/) (American College of Rheumatology, ACR; members earn no direct revenue from losartan). Conventional reference: about 3.4–7.0 mg/dL in men and 2.4–6.0 mg/dL in women, varying by laboratory. |
| Hemoglobin | 13.5–17.5 g/dL in men and 12.0–15.5 g/dL in women (standard reference range) | Safety check: a meaningful fall prompts review | Losartan lowers hemoglobin modestly ([Mohanram et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18094675/)); compare with own baseline; part of a complete blood count. |
| Pregnancy test | Negative (standard reference range) | Safety check: a positive result stops use | Before starting and whenever pregnancy is possible. |

Qualitative markers of success and safety:

* Dizziness or light-headedness on standing
* Energy, fatigue, and exercise tolerance
* Muscle cramps or weakness (possible potassium change)
* Swelling of lips, tongue, face, or throat (a possible sign of angioedema)
* Sleep quality and nighttime urination
* Cognitive clarity and mood

  
## Emerging Research

* **Knee injury recovery ([NCT06933706](https://clinicaltrials.gov/study/NCT06933706)):** Recruiting phase 2 placebo-controlled trial (90 participants; 25 mg for 30 days after multi-ligament knee surgery) measuring return to work or sport; completion 2029. A positive result would support losartan's anti-scarring role in tissue repair; a null result would weaken extrapolation from mouse data.
* **Arthrofibrosis (joint scarring) after knee replacement ([NCT06108063](https://clinicaltrials.gov/study/NCT06108063)):** Recruiting phase 1/2 placebo-controlled trial (120 participants) after surgery, measuring joint-capsule thickness and range of motion; completion 2027. A positive result would extend the anti-fibrotic case to older adults; a null result would narrow it.
* **Radiation fibrosis and senescence markers ([NCT05637216](https://clinicaltrials.gov/study/NCT05637216)):** Phase 2 trial (43 participants; 25 mg vs placebo) in irradiated breast cancer patients, measuring fibrosis and cellular senescence (aging-cell) biomarkers; active, completion 2027. A positive result would give a first human senescence signal; a null result would weaken the aging rationale.
* **Pancreatic cancer combination ([NCT03563248](https://clinicaltrials.gov/study/NCT03563248)):** Randomized phase 2 trial (168 participants) of losartan plus nivolumab (an immunotherapy drug) with chemotherapy; primary completion passed in 2022 with no results posted or found on PubMed; full completion 2027. A positive result would support tumor-scar-loosening add-on use; a null result would weaken it.
* **Losartan and reward learning ([NCT07017023](https://clinicaltrials.gov/study/NCT07017023)):** Early-phase trial (76 volunteers; 50 mg for 7 days with behavioural activation, a structured activity-scheduling therapy) testing reinforcement learning in low mood; completion December 2026. A positive result would suggest mood-relevant brain effects; a null result would argue against them.
* **Longevity trials:** Aging researchers propose human trials of renin-angiotensin blockers, even at low doses ([de Cavanagh et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38924381/)); no ClinicalTrials.gov trial testing losartan on aging outcomes in healthy adults was found. Such a trial could confirm or refute the mouse longevity signal.
* **Mortality versus ACE inhibitors:** Pooled data suggest a class mortality gap ([van Vark et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22511654/)), while head-to-head Cochrane data show none ([Li et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25148386/)); new head-to-head data could strengthen or weaken losartan's case as a first choice.
* **Fatty liver disease:** Small trials show lower liver enzymes ([Meng et al., 2023](https://pubmed.ncbi.nlm.nih.gov/36970603/)); larger biopsy-based trials would show whether this means less liver scarring or merely a marker change.

  
## Conclusion

Losartan is an inexpensive, well-studied blood pressure drug that blocks a hormone that narrows blood vessels and retains salt. Its strongest evidence covers reliable blood pressure lowering and slower kidney decline in people with diabetic or protein-leaking kidney disease. Moderate evidence links it to fewer strokes, less new diabetes, fewer irregular heart rhythms, and fewer heart failure admissions, although several comparisons were against an older drug rather than a placebo, and in heart failure it has not matched a related drug type on survival. It also modestly lowers uric acid.

The longevity case rests mainly on animal work: mice unable to respond to this hormone live longer, and rodent studies show protection of cellular energy machinery and muscle repair. Human tests of survival across the drug class, brain shrinkage in Alzheimer's disease, and mobility in older adults have not shown benefit.

The main risks are high blood potassium, low blood pressure, reduced kidney filtering in vulnerable situations, and serious harm to a developing baby during pregnancy; contamination recalls also affected some generic supplies. These risks are predictable and trackable with simple blood tests and home readings.

Much of the large-trial evidence was funded by the original manufacturer, while the guideline groups cited here do not profit directly from its use. For health-focused adults with raised blood pressure or kidney concerns, the documented benefits are substantial, with a small added uric-acid effect; for people with normal blood pressure pursuing a longer life, the evidence remains limited to animal studies.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**